1. Home
  2. FINV vs AGIO Comparison

FINV vs AGIO Comparison

Compare FINV & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FINV

FinVolution Group

HOLD

Current Price

$5.64

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.98

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FINV
AGIO
Founded
2007
2007
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
FINV
AGIO
Price
$5.64
$27.98
Analyst Decision
Strong Buy
Buy
Analyst Count
2
8
Target Price
$11.55
$37.63
AVG Volume (30 Days)
1.1M
664.7K
Earning Date
03-16-2026
04-30-2026
Dividend Yield
5.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
$6.02
$75.68
Revenue Next Year
N/A
$167.63
P/E Ratio
$3.87
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.70
$22.24
52 Week High
$10.90
$46.00

Technical Indicators

Market Signals
Indicator
FINV
AGIO
Relative Strength Index (RSI) 52.08 46.39
Support Level $5.44 $26.48
Resistance Level $5.96 $29.49
Average True Range (ATR) 0.25 1.06
MACD 0.04 -0.06
Stochastic Oscillator 34.96 29.67

Price Performance

Historical Comparison
FINV
AGIO

About FINV FinVolution Group

FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: